Phase II Evaluation of Docetaxel Combined With Estramustine Phosphate in Patients With Metastatic Breast Cancer
OBJECTIVES: I. Determine the response rate, duration of response, duration of survival, and
quality of life effects of docetaxel and estramustine combination in women with metastatic
breast cancer.
OUTLINE: Patients receive estramustine 3 times a day for 3 days. Docetaxel begins on day 3
after the a.m. dose of estramustine and is given as a 1 hour infusion intravenously. Courses
repeat every 21 days. If disease responds or is stable, treatment continues at the highest
tolerance percentage of prescribed dose until appearance of disease progression. If complete
response is documented, an additional 2 courses are given. Patients should receive a minimum
of 2 courses unless rapid progression or unacceptable toxicity occur. Patients are followed
monthly.
PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Amy D. Tiersten, MD
Study Chair
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
CDR0000065737
NCT00003066
February 1997
Name | Location |
---|---|
Herbert Irving Comprehensive Cancer Center | New York, New York 10032 |